{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T04:29:42Z","timestamp":1691123382933},"reference-count":22,"publisher":"South Florida Publishing LLC","issue":"8","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Foco"],"abstract":"<jats:p>Introdu\u00e7\u00e3o: A psor\u00edase \u00e9 uma doen\u00e7a inflamat\u00f3ria cr\u00f3nica n\u00e3o contagiosa, que afeta o tecido cut\u00e2neo, sendo caracterizada pela forma\u00e7\u00e3o de placas avermelhadas, endurecidas e com tend\u00eancia a escama\u00e7\u00e3o na pele que pode tamb\u00e9m afetar unhas e articula\u00e7\u00f5es. A etiologia da psor\u00edase ainda n\u00e3o \u00e9 bem conhecida, mas, atualmente, est\u00e1 relacionada \u00e0s seguintes causas: predisposi\u00e7\u00e3o gen\u00e9tica, agentes extr\u00ednsecos como queimaduras solares, infe\u00e7\u00f5es, f\u00e1rmacos sist\u00e9micos e stress e, ainda, o sistema imunit\u00e1rio. O tratamento \u00e9 uma conjuga\u00e7\u00e3o de medidas farmacol\u00f3gicas e n\u00e3o farmacol\u00f3gicas. A psor\u00edase \u00e9 associada a v\u00e1rias comorbilidades do foro cardiovascular, metab\u00f3lico, cerebrovascular, psicol\u00f3gico e entre outros. Objetivos: O objetivo deste artigo \u00e9 verificar o conhecimento das causas da psor\u00edase, e a terap\u00eautica associada, real\u00e7ando a sua efic\u00e1cia e seguran\u00e7a e, ainda, as suas comorbilidades. Material e M\u00e9todos: A pesquisa bibliogr\u00e1fica foi realizada em bases de dados como PubMed, Google Scholar e Medline Plus, usando as palavras-chave \u201cPsoriasis\u201d; \u201cComorbidity\u201d; \u201cSkin Structure\u201d; \u201cTreatment\u201d; \u201cUnconventional Treatment\u201d; \u201cPathogenesis\u201d: \u201cIchthyotherapy\u201d. \u00a0Resultados: O tratamento adequado da psor\u00edase \u00e9 crucial para melhorar o quadro cl\u00ednico, podendo ser realizado a partir de v\u00e1rias alternativas. \u00c9 muito usual o uso de terap\u00eautica t\u00f3pica a partir de corticoides, an\u00e1logos da vitamina D, tazaroteno e inibidores da calcineurina, na doen\u00e7a leve e moderada. Quando a psor\u00edase \u00e9 severa \u00e9 tratada com terapia sist\u00e9mica (metotrexato, ciclosporina, acitretina e terapia biol\u00f3gica) associada a fototerapia. As comorbilidades mais comuns da psor\u00edase s\u00e3o doen\u00e7as cardiovasculares como hipertens\u00e3o e doen\u00e7a arterial coron\u00e1ria, doen\u00e7as metab\u00f3licas como diabetes, obesidade e comprometimento articular como \u00e9 o caso da arterite psori\u00e1tica. Conclus\u00e3o: \u00c9 de grande import\u00e2ncia o estudo da rela\u00e7\u00e3o entre o bin\u00f3mio psor\u00edase-comorbilidades. Os estudos at\u00e9 agora efetuados, apresentam perspetivas promissoras para melhorar o tratamento, diagnosticar e tratar as comorbilidades.<\/jats:p>","DOI":"10.54751\/revistafoco.v16n8-033","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T14:32:12Z","timestamp":1691073132000},"page":"e2754","source":"Crossref","is-referenced-by-count":0,"title":["COMORBILIDADES NA PSOR\u00cdASE: REVIS\u00c3O BIBLIOGR\u00c1FICA"],"prefix":"10.54751","volume":"16","author":[{"given":"Oriana Stephania Moreira","family":"Betancourt","sequence":"first","affiliation":[]},{"given":"Ana Paula Gomes","family":"Fonseca","sequence":"additional","affiliation":[]},{"given":"Z\u00e9lia Rosa da Silva Barbosa","family":"Moreia","sequence":"additional","affiliation":[]}],"member":"30764","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"51103","doi-asserted-by":"crossref","unstructured":"Chambers ES, Vukmanovic-Stejic M. Skin barrier immunity and ageing. Immunology. Jun 1;160(2):116\u201325, 2020","DOI":"10.1111\/imm.13152"},{"key":"51104","unstructured":"Kim W, Jerone D, Yeung Jensen. Diagnosis and management of psoriasis. Can Fam Physician [Internet]. Apr;278\u201385. Available from: www.cfp.ca, 2017"},{"key":"51105","unstructured":"Medline Plus. Psoriasis_ MedlinePlus Medical Encyclopedia. In Medline Plus, Available from: https:\/\/medlineplus.gov\/ency\/article\/000434.htm,2021."},{"key":"51106","doi-asserted-by":"crossref","unstructured":"Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. Oct 2;21(20):1\u201316,2020.","DOI":"10.3390\/ijms21207488"},{"key":"51107","doi-asserted-by":"crossref","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. Mar 2;20(6), 2019.","DOI":"10.3390\/ijms20061475"},{"key":"51108","unstructured":"World Health Organization. Global report on psoriasis. World Health Organization; 2016."},{"key":"51109","doi-asserted-by":"crossref","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? British Journal of Dermatology. Apr 1;182(4):840\u20138,2020.","DOI":"10.1111\/bjd.18245"},{"key":"51110","doi-asserted-by":"crossref","unstructured":"Neema S, Sandhu S, Gupta A, Jagadeesan S, Vasudevan B. Unconventional treatment options in psoriasis: A review. Indian J Dermatol Venereol Leprol. Mar 1;88(2):137\u201343,2022.","DOI":"10.25259\/IJDVL_22_2021"},{"key":"51111","doi-asserted-by":"crossref","unstructured":"Reid C, Griffiths CEM. Psoriasis and treatment: Past, present and future aspects. Acta Derm Venereol;100(100-year theme Psoriasis):69\u201379,2020.","DOI":"10.2340\/00015555-3386"},{"key":"51112","unstructured":"Weigle N, Mcbane S. Psoriasis [Internet]. Vol. 87.. Available from: www.aafp.org\/afp,2013."},{"key":"51113","doi-asserted-by":"crossref","unstructured":"De Oliveira Fran\u00e7a ML, Vieira Lena A, Nakamura J, De Souza Bukoski L, De Souza Braga L. Caracteriza\u00e7\u00e3o da psor\u00edase e seu tratamento: uma revis\u00e3o narrativa. SaBios-Revista de Sa\u00fade e Biologia. Nov 4;16:1\u201313,2021.","DOI":"10.54372\/sb.2021.v16.2428"},{"key":"51114","doi-asserted-by":"crossref","unstructured":"Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers Med Sci. Jan 1;33(1):173\u201380,2018.","DOI":"10.1007\/s10103-017-2360-1"},{"key":"51115","doi-asserted-by":"crossref","unstructured":"Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson Comorbidity Index: A Critical Review of Clinimetric Properties. Psychother Psychosom. Jan 1;91(1):8\u201335,2022.","DOI":"10.1159\/000521288"},{"key":"51116","doi-asserted-by":"crossref","unstructured":"Amin M, Lee EB, Tsai TF, Wu JJ. Psoriasis and co-morbidity. Acta Derm Venereol;100(100-year theme Psoriasis):80\u20136,2020.","DOI":"10.2340\/00015555-3387"},{"key":"51117","doi-asserted-by":"crossref","unstructured":"Yamazaki F. Psoriasis: Comorbidities. Journal of Dermatology. Jun 1;48(6):732\u201340,2021.","DOI":"10.1111\/1346-8138.15840"},{"key":"51118","doi-asserted-by":"crossref","unstructured":"Nikam RV, Gowtham M, More PS, Shinde AS. Current and emerging prospects in the psoriatic treatment. Int Immunopharmacol. Jul 1;120, 2023.","DOI":"10.1016\/j.intimp.2023.110331"},{"key":"51119","doi-asserted-by":"crossref","unstructured":"Potestio L, Ruggiero A, Fabbrocini G, Martora F, Megna M. Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature. Psoriasis: Targets and Therapy [Internet]. May;Volume 13:19\u201326. Available from: https:\/\/www.dovepress.com\/effectiveness-and-safety-of-deucravacitinib-for-the-management-of-psor-peer-reviewed-fulltext-article-PTT, 2023.","DOI":"10.2147\/PTT.S407647"},{"key":"51120","doi-asserted-by":"crossref","unstructured":"Antonatos C, Asmenoudi P, Panoutsopoulou M, Vasilopoulos Y. Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine. Int J Mol Sci. Apr 1;24(8), 2023.","DOI":"10.3390\/ijms24087090"},{"key":"51121","doi-asserted-by":"crossref","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol. Mar 1;76(3):393\u2013403, 2017.","DOI":"10.1016\/j.jaad.2016.07.065"},{"key":"51122","doi-asserted-by":"crossref","unstructured":"Hao Y, Zhu YJ, Zou S, Zhou P, Hu YW, Zhao QX, et al. Metabolic Syndrome and Psoriasis: Mechanisms and Future Directions. Front Immunol. Jul 23;12,2021.","DOI":"10.3389\/fimmu.2021.711060"},{"key":"51123","doi-asserted-by":"crossref","unstructured":"Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: Causes and consequences. Front Immunol. Apr 5;9(APR), 2018.","DOI":"10.3389\/fimmu.2018.00579"},{"key":"51124","doi-asserted-by":"crossref","unstructured":"Tashiro T, Sawada Y. Psoriasis and Systemic Inflammatory Disorders. Int J Mol Sci. Apr 1;23(8), 2022.","DOI":"10.3390\/ijms23084457"}],"container-title":["REVISTA FOCO"],"original-title":[],"link":[{"URL":"https:\/\/ojs.focopublicacoes.com.br\/foco\/article\/download\/2754\/1767","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ojs.focopublicacoes.com.br\/foco\/article\/download\/2754\/1767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T14:32:20Z","timestamp":1691073140000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojs.focopublicacoes.com.br\/foco\/article\/view\/2754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,7,31]]}},"URL":"https:\/\/doi.org\/10.54751\/revistafoco.v16n8-033","relation":{},"ISSN":["1981-223X"],"issn-type":[{"value":"1981-223X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]}}}